{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen R"],"funding":["Fundamental Research Funds for the Central Universities","Guangzhou Basic and Applied Basic Research Program","Special Research and Development Program of Guangzhou","Important Key Program of Natural Science Foundation of China","Pearl River S and T Nova Program of Guangzhou","Special 2019-nCoV Program of NSFC","National Natural Science Foundation of China","High-level Biosafety Laboratory Construction Program of the Science and Technology Projects of Guangdong Province of China","Emergency Key Program of Guangzhou Laboratory","Exchange Program of NSFC","Shenzhen Science and Technology Program"],"pagination":["e2105378"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9008796"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(11)"],"pubmed_abstract":["The SARS-CoV-2 Delta (B.1.617.2) strain is a variant of concern (VOC) that has become the dominant strain worldwide in 2021. Its transmission capacity is approximately twice that of the original strain, with a shorter incubation period and higher viral load during infection. Importantly, the breakthrough infections of the Delta variant have continued to emerge in the first-generation vaccine recipients. There is thus an urgent need to develop a novel vaccine with SARS-CoV-2 variants as the major target. Here, receptor binding domain (RBD)-conjugated nanoparticle vaccines targeting the Delta variant, as well as the early and Beta/Gamma strains, are developed. Under both a single-dose and a prime-boost strategy, these RBD-conjugated nanoparticle vaccines induce the abundant neutralizing anti"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants."],"pmcid":["PMC9008796"],"funding_grant_id":["201806010118","2021B1212030012","32100743","82150710553","82041002","JCYJ20200109142601702","202102021094","EKPG21-24","92169201","81971918","202102021058","202008070010","2021qntd43","JSGG20200225150431472","81730060","82171825"],"pubmed_authors":["Peng Y","Zhang H","Deng J","Wu B","Deng K","Wang G","Lin Y","Zou F","Liang C","Wu S","Liang L","Wang X","Chen R","Deng X","Yuan Y","Zhou M","Xi Z","Li C","Pan T","Li R","Li Y","Bu X","Zhang Z","Zhang Y","Zhang X","He X","Yan H","Ke C"],"additional_accession":[]},"is_claimable":false,"name":"Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.","description":"The SARS-CoV-2 Delta (B.1.617.2) strain is a variant of concern (VOC) that has become the dominant strain worldwide in 2021. Its transmission capacity is approximately twice that of the original strain, with a shorter incubation period and higher viral load during infection. Importantly, the breakthrough infections of the Delta variant have continued to emerge in the first-generation vaccine recipients. There is thus an urgent need to develop a novel vaccine with SARS-CoV-2 variants as the major target. Here, receptor binding domain (RBD)-conjugated nanoparticle vaccines targeting the Delta variant, as well as the early and Beta/Gamma strains, are developed. Under both a single-dose and a prime-boost strategy, these RBD-conjugated nanoparticle vaccines induce the abundant neutralizing anti","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-05T00:40:03.296Z","creation":"2024-11-15T17:04:57.924Z"},"accession":"S-EPMC9008796","cross_references":{"pubmed":["35142444"],"doi":["10.1002/advs.202105378"]}}